Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors

Journal of Medical Virology

Volumn 83, Issue 5, 2011, Pages 751-759

  Brenner, Bluma G ^a,b   Lowe, Matthew ^a,b   Moisi, Daniela ^a   Hardy, Isabelle ^b   Gagnon, Simon ^b   Charest, Hugues ^c   Baril, Jean Guy ^d   Wainberg, Mark A ^a,b   Roger, Michel ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d Clinique Medicale du Quartier Latin   (Canada)

Author keywords

Drug resistance; Genotyping and phylogenetics; HIV subtypes; HIV 1; Integrase

Indexed keywords

PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; NONHUMAN; PHYLOGENY; VIRUS TRANSMISSION;

AMINO ACID SUBSTITUTION; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952711748     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22047     Document Type: Article

References (65)

1. Abebe A, Pollakis G, Fontanet AL, Fisseha B, Tegbaru B, Kliphuis A, Tesfaye G, Negassa H, Cornelissen M, Goudsmit J, Rinke de Wit TF. 2000. Identification of a genetic subcluster of HIV type 1 subtype C (C′) widespread in Ethiopia. AIDS Res Hum Retroviruses 16: 1909-1914.
2. Akouamba BS, Viel J, Charest H, Merindol N, Samson J, Lapointe N, Brenner BG, Lalonde R, Harrigan PR, Boucher M, Soudeyns H. 2005. HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis 11: 1230-1234.
3. Ayele W, Mekonnen Y, Messele T, Mengistu Y, Tsegaye A, Bakker M, Berkhout B, Dorigo-Zetsma W, Wolday D, Goudsmit J, Coutinho R, de Baar M, Paxton WA, Pollakis G. 2010. Differences in HIV type 1 RNA plasma load profile of closely related cocirculating Ethiopian subtype C strains: C and C′. AIDS Res Hum Retroviruses 26: 805-813.
4. Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A. 2009. Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study. J Clin Virol 46: 290-294.
5. Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett J Jr, Harris B, Holzmayer V, Luk KC, Schochetman G, Swanson P, Yamaguchi J, Vallari A, Ndembi N, Ngansop C, Makamche F, Mbanya D, Gurtler LG, Zekeng L, Kaptue L. 2008. The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr 49: 432-439.
6. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17: F1-5.
7. Brenner BG. 2007. Resistance and viral subtypes: how important are the differences and why do they occur? Curr Opin HIV AIDS 2: 94-102.
8. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20: F9-F13.
9. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA. 2008. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 22: 2509-2515.
10. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA. 2007. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 195: 951-959.
11. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. 2002a. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76: 1753-1761.
12. Brenner BG, Turner D, Wainberg MA. 2002b. HIV-1 drug resistance: can we overcome? Expert Opin Biol Ther 2: 751-761.
13. Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J. 2010. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
14. Buzon MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C. 2008. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther 13: 881-893.
15. Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM. 2009. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol 81: 1323-1335.
16. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. 2009. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 11: 17-29.
17. Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C. 2008. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 9: 765-770.
18. Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L. 2010. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 24: 867-873.
19. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359: 355-365.
20. Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. 2010. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother 20: 117-131.
21. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA. 2009. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 83: 2029-2033.
22. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B. 2010. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65: 1262-1269.
23. De Luca A, Di Giambenedetto S, Cingolani A, Bacarelli A, Ammassari A, Cauda R. 2006. Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. Antivir Ther 11: 321-327.
24. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 37: 1193-1201.
25. Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F. 2006. Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: a meta-analysis. Enferm Infecc Microbiol Clin 24: 232-237.
26. Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, Devare SG, Marlowe N. 2009. Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses 25: 343-345.
27. Felsenstein J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39: 783-791.
28. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. 2010. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 26: 489-493.
29. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, Huang W. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83: 11440-11446.
30. Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 65: 320-326.
31. Hall TA. 1999. Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symp 41: 95-98.
32. Hemelaar J, Gouws E, Ghys PD, Osmanov S. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-23.
33. Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J, Fujisaki S, Iwatani Y, Mamiya N, Utsumi M, Kato S, Hamaguchi M, Sugiura W. 2010. HIV-2 CRF01-AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr 54: 241-247.
34. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. 2009. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 200: 1202-1206.
35. Kumar S, Tamura K, Jakobsen IB, Nei M. 2001. MEG A2: molecular evolutionary genetics analysis software. Bioinformatics 17: 1244-1245.
36. Lataillade M, Chiarella J, Kozal MJ. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570.
37. Liitsola K, Holm K, Bobkov A, Pokrovsky V, Smolskaya T, Leinikki P, Osmanov S, Salminen M. 2000. An AB recombinant and its parental HIV type 1 strains in the area of the former Soviet Union: low requirements for sequence identity in recombination. UNAIDS Virus Isolation Network. AIDS Res Hum Retroviruses 16: 1047-1053.
38. Liitsola K, Tashkinova I, Laukkanen T, Korovina G, Smolskaja T, Momot O, Mashkilleyson N, Chaplinskas S, Brummer-Korvenkontio H, Vanhatalo J, Leinikki P, Salminen MO. 1998. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. AIDS 12: 1907-1919.
39. Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M. 2009. Natural polymorphisms of HIV-1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 53: 4275-4282.
40. Lukashov VV, Huismans R, Rakhmanova AG, Lisitsina ZN, Akhtyrskaya NA, Vlasov NN, Melnick OB, Goudsmit J. 1999. Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. AIDS Res Hum Retroviruses 15: 1577-1583.
41. Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cisse M, Katlama C, Calvez V, Marcelin AG. 2009. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02-AG subtypes. Antivir Ther 14: 123-129.
42. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. 2009. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63: 795-804.
43. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52: 1351-1358.
44. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD. 2003. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
45. Myers RE, Pillay D. 2008. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 82: 9228-9235.
46. Passaes CB, Guimaraes ML, Fernandez SL, Lorete Rdos S, Teixeira SL, Fernandez JC, Morgado MG. 2009. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr 51: 7-12.
47. Pillay D, Rambaut A, Geretti AM, Brown AJ. 2007. HIV phylogenetics. BMJ 335: 460-461.
48. Pollakis G, Abebe A, Kliphuis A, De Wit TF, Fisseha B, Tegbaru B, Tesfaye G, Negassa H, Mengistu Y, Fontanet AL, Cornelissen M, Goudsmit J. 2003. Recombination of HIV type 1C (C'/C″) in Ethiopia: possible link of EthHIV-1C' to subtype C sequences from the high-prevalence epidemics in India and Southern Africa. AIDS Res Hum Retroviruses 19: 999-1008.
49. Pommier Y, Johnson AA, Marchand C. 2005. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 4: 236-248.
50. Quercia R, Dam E, Perez-Bercoff D, Clavel F. 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 83: 10245-10249.
51. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW. 2008. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 5: 74.
52. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14: F17-23.
53. Serrao E, Odde S, Ramkumar K, Neamati N. 2009. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 6: 25.
54. Shimura K, Kodama EN. 2009. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 20: 79-85.
55. Soares EA, Martinez AM, Souza TM, Santos AF, Da Hora V, Silveira J, Bastos FI, Tanuri A, Soares MA. 2005. HIV-1 subtype C dissemination in southern Brazil. AIDS 19: S81-86.
56. Soares EA, Santos AF, Sousa TM, Sprinz E, Martinez AM, Silveira J, Tanuri A, Soares MA. 2007. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2: e730.
57. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
58. Tully DC, Wood C. 2010. Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia. AIDS 24: 1577-1582.
59. Turner D, Wainberg MA. 2006. HIV transmission and primary drug resistance. AIDS Rev 8: 17-23.
60. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. 2008. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 22: 1877-1880.
61. van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2006. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41: 352-360.
62. Van Laethem K, Schrooten Y, Covens K, Dekeersmaeker N, De Munter P, Van Wijngaerden E, Van Ranst M, Vandamme AM. 2008. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 153: 176-181.
63. Van Maele B, Debyser Z. 2005. HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Rev 7: 26-43.
64. Wainberg MA, Friedland G. 1998. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279: 1977-1983.
65. Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F, Tozzi V, Forbici F, Gori C, Trotta MP, Boumis E, Narciso P, Perno CF, Antinori A. 2009. Historical resistance profile helps to predict salvage failure. Antivir Ther 14: 285-291.